Images and logos
Drug Discovery Today covers Kancera's Fractalkine project
Kancera Project Update Feb. 2017
Poster at ASH on ROR inhibitors
Presentation by CEO Thomas Olin in Paris at BIO-Europe Spring 2015
Now is also the english version of the Kancera homepage updated.
You can now follow Kancera on LinkedIn
Japanese scientists have identified ROR1 as an Achilles heel in a difficult to treat lung cancer.
iNovacia AB has developed active compounds as a step towards treatment of a serious parasitic disease
Kancera has filed patent for new active substances against cancer
Welcome to share subscription in Kancera AB (publ)
Anders Essen-Möller and Bernt Magnusson to Kancera's Board of Directors
Thomas Olin, CEO
Tel.: +46 (0)850 12 60 80
Copyright 2010 KANCERA AB, KAROLINSKA INSTITUTET SCIENCE PARK, BANVAKTSVÄGEN 22, 171 48 SOLNA. TEL: +46 (0)850 12 60 80